摘要
目的应用酶联免疫吸附实验(ELISA)检测MR靶向对比剂前体——血管内皮生长因子165-适配体(VEGF165-aptamer)与VEGF165的体外结合能力,以了解其对VEGF的靶向性。方法实验组采用亲和素96孔酶标板,包被生物素化VEGF165-aptamer,设置递减的浓度梯度(共9组)和空白对照组,采用组间方差分析。结果实验组包被生物素化VEGF165-aptamer浓度在50～0.78pmol/μL时,实验组与空白组及实验各相邻组间差异有统计学意义(P<0.05);实验组包被浓度为0.39、0.195pmol/μL时,两组与空白组间及两组间差异均无统计学意义(P>0.05)。结论采用ELISA检测技术验证了VEGF165-aptamer与VEGF165间的体外结合能力,其有效最低小包被浓度为0.78pmol/μL,VEGF165-aptamer对VEGF165有良好的靶向性。
Objective To investigate the binding ability of MR target contrast agent precursor-vascular endothelial growth factor 165 (VEGF165)-aptamer with VEGF165 in vitro using enzyme-linked immunosorbent assay method. Methods In the test groups,the biotinylation VEGF165-aptamer was coated onto the 96 well plates with gradient concentrations from 50 pmol/μL to 0.195 pmol/μL. The corresponding control groups were also set up. The data were analyzed with One-way ANOVA. The binding between VEGF165-aptamer and VEGF165 w...
出处
《国际医学放射学杂志》
2011年第1期9-11,共3页
International Journal of Medical Radiology
基金
国家自然科学基金(30760059)
关键词
VEGF
适配体
酶联免疫吸附实验
VEGF
Adaptation body
Enzyme-linked immunosorbent assay method
